Abstract
Background: Attempts to optimize DNA vaccines in mice include using different routes of administration and different formulations. It may be more relevant to human use to carry such studies out in nonhuman primates. Here we compare different approaches to delivery of a DNA vaccine against the hepatitis B virus (HBV) in Aotus monkeys. Materials and Methods: Thirty-two adult Aotus 1. lemurinus monkeys divided into 8 groups of four were immunized with 400 ,tg of a DNA vaccine which encoded hepatitis B surface antigen (HBsAg). DNA in saline was administered by intradermal (ID) (10 ,ug) adsorbed onto alum. Monkeys were boosted in an identical fashion to their prime at 8 weeks, but all received the protein vaccine (Engerix-B) at 16 weeks. Sera was assessed for antibodies against HBsAg (anti-HBs) by enzyme-linked imunosorbent assay (ELISA).
Results: The primary humoral response induced by IM delivery of the DNA vaccine was very poor. In most cases there was no detectable anti-HBs even after 2 DNA doses but the kinetics of the response to subsequent protein indicated that a memory B cell response had been induced. In contrast, following IM-administration of DNA using the Biojector, detectable anti-HBs were observed in 3 of 8 animals and evidence for immunological priming was apparent in an additional 4 of the 8 monkeys. ID injection of DNA vaccine in saline induced a potent antibody response which was augmented 6-fold by the addition of E. coli DNA. Combining ID and IM administration did not improve humoral immunity over ID injection alone. Conclusions: For immunization of primates with DNA vaccines, UD may be a preferable route to IM, although it is not dear whether the Aots monkey is a relevant model for humans in this respect. Nevertheless, the use of the Biojector needleless injection system may improve responses with IM delivery of DNA vaccines. As well, the immunostimulatory action of E. coli DNA may be used to augrnent the humoral response induced by a DNA vaccine.
Introduction
DNA-based immunization has been shown to be highly effective in inducing humoral and cellmediated immunity against numerous viral, bacterial, and parasitic diseases in many animal models. These studies have shown that DNA vaccines may be delivered by various routes in different formulations, including intramuscular (IM) and intradermal (ID) injection of pure plasmid DNA, epidermal delivery of DNA-coated gold particles delivered biolistically with a "genegun," and IM injection of liposome-formulated DNA (1) (2) (3) (4) . It is difficult to evaluate the relative efficacy of these approaches as there has been very little comparative data using the same antigen and animal model.
Although several DNA vaccines have been shown to be effective in nonhuman primates (5) (6) (7) (8) (9) (10) (11) (12) , most of these used only IM injection of DNA. As such, it is unclear which routes work in primates and what their relative efficacy might be. In addition, there is generally a need to optimize DNA vaccines in primates in order to reduce the dose of DNA or the number of immunizations required to induce adequate immunity.
We have used the Aotus monkey and a DNA vaccine against the hepatitis B virus (HBV) to evaluate the humoral response against HBV surface antigen (HBsAg) after IM and ID injection of pure plasmid DNA. We have also evaluated the possibility of optimizing these responses through the use of a needleless injection system for IM delivery, the use of liposome-formulated DNA, and the co-administration of Escherichia coli (E. coli) DNA to take advantage of the adjuvant effect of immunostimulatory CpG motifs.
Materials and Methods
Monkeys Adult male and female Aotus lemurinus lemurinus (karyotype VIII or IX) monkeys (weight 650-1000 g) were maintained in the animal facility of the Gorgas Memorial Laboratory in Panama City, Panama. All A. 1. lemurinus monkeys were caught wild on the Isthmus of Panama. Upon arrival at the laboratory, each animal was examined, weighed, and sexed, identified by a metal neck tag with an accession number, administered thiabendazole orally (100 mg base/kg), and vaccinated against Herpes simplex, Herpes tamarinus (New England Regional Primate Research Center, Southborough, MA) and Klebsiella pneumoniae (N. Obaldia, Gorgas Memorial Laboratory, Panama City, Panama). Pre-immune sera from all monkeys was negative for pre-existing antibodies against hepatitis B surface antigen. Throughout the course of the study, the monkeys were monitored daily by animal care specialists and no symptoms of general ill health or local adverse reactions at the sites of injection were noted.
Monkeys were housed either singly, as male/ female pairs, or as family units with up to two offspring per adult pair. Room temperature varied seasonally from 260 to 33°C, with relative humidity of 75% to 87%. A ventilation system provided not less than 15 air changes per hour. Illumination in the rooms was white light from midnight to noon, and red light from noon to midnight.
Experimental Groups
The monkeys were divided randomly into 9 groups of 4 animals each. For 8 groups, the animals were immunized by IM and/or ID injection of an HBsAg-expressing plasmid DNA vaccine, and boosted in an identical manner 8 weeks later. The DNA was given in saline, formulated with cationic liposomes or with added E. coli DNA, and delivered with an ordinary needle and syringe (IM and ID) or with a needleless jet injection system (IM only). The ninth group received a commercial vaccine containing recombinant HBsAg at 0 and 8 weeks. All groups received the recombinant HBsAg vaccine at 16 weeks to evaluate booster or anamnestic responses. Details for the different groups are summarized in Table 1 .
Vaccines and Formulations
PLASMID DNA VACCINE. The DNA vaccine was a plasmid encoding the major protein (S, ad subtype) of the HBV envelope under the control of the cytomegalovirus (CMV) immediate early promoter and containing intron A of CMV (pCMVA-S; provided by G. Widera, PowderJect, Inc., Madison, WI). The plasmid was grown using its kanamycin resistance gene as a selection marker and the DNA was purified on Qiagen anion-exchange chromatography columns (Qiagen GmbH, Hilden, Germany). Purified DNA was Anti-HBs titers were expressed as group means ± standard errors of the mean (SEM) of individual animal values, which were themselves the average of triplicate assays. The relationship between end-point dilution titers and those in milli-International Units/ml (mIU/ml), as defined by the World Health Organization (WHO), was determined by comparing a panel of Aotus sera against human-derived standards (Monolisa Anti-HBs "Standards," Sanofi Diagnostics Pasteur, Montreal, Canada) using a nonspecies-specific conjugate (Monolisa Anti-HBs Detection Kit, Sanofi Diagnostics Pasteur) and found to be very close to 1:1. An antibody titer of 10 mIU/ml is considered protective against HBV infection in humans (13, 14) . For the purpose of this study, we defined seroconversion as a dilution titer greater than 10. Results Intramuscular Delivery of DNA Vaccines IM administration of the HBsAg-expressing DNA vaccine (in saline or with lipid) with an ordinary needle and syringe did not result in seroconversion of any monkey, even after 2 doses. However, 4 of 8 animals seroconverted in response to recombinant protein given subsequently, and in three of these, the response appeared faster than after priming with protein ( Fig. 1 , Panels D and G versus A), indicating induction of immunological memory.
The anti-HBs response with IM-delivered DNA vaccine was somewhat improved using needle-free jet injection (Biojector). In this case, 3 of 8 animals seroconverted after the second dose of DNA, and there appeared to be immunological priming by the DNA in another four, as evidenced by the rapid response to subsequently delivered protein (Figs. 1E, H, 2 (Fig. 1I ), but had a strong immunostimulatory effect after ID delivery, where the mean anti-HBs titer after 2 doses of DNA was up to 4-fold higher than DNA vaccine alone (Fig. 1C) . The immunostimulatory effect of the E. coli DNA was even more evident after the protein boost, at which time a 6-fold difference in mean anti-HBs titer was detected (Figs. IC, 2 ).
Protein Immunization
After the initial dose of recombinant HBsAg (Engerix-B), only 1 of 4 monkeys seroconverted, and this was not detected until 6 weeks. All 4 monkeys were seropositive after the second dose of protein, and titers were further increased by the third dose (Figs. lA, 2 (16) . In humans, females are known to respond better than males to HBsAg, but no gender differences were noted for Aotus monkeys.
The suitability of the Aotus monkey as a model for humans with respect to efficiency of gene transfer and antigen expression is more difficult to ascertain. In mice, the HBsAg-expressing DNA vaccine works better when given IM than ID in equal doses (Brazolot Millan et al., unpublished observations). Here, we show that in Aotus monkeys, the ID route is better than IM, which essentially doesn't work unless the DNA formulation and method of delivery is optimized. This may not be very representative of the human situation, since IM-delivered DNA vaccines expressing HBsAg are effective in chimpanzees (6, 12) and Rhesus macaque monkeys (Brazolot Millan et al., unpublished observations). Furthermore, using a malaria DNA vaccine model in Aotus monkeys, we have found the IM route to be completely ineffective for induction of antibodies against P. yoelii and P. falciparum circumsporozoite protein (PyCSP, PfCSP), even though ID delivery of the same DNA vaccines or IM injection of a malaria multiple antigen peptide vaccine in adjuvant gives high levels of PyCSPor PfCSP-specific antibodies (17, 18) (19) . Nevertheless, in addition to the HBsAg and malaria DNA vaccines mentioned above (6, 12, 17, 18) , other DNA vaccines have been effective after IM delivery to nonhuman primates, including those encoding various proteins from influenza A or herpes simplex virus in African green monkeys (10) and from HIV/SIV in Rhesus macaque monkeys (8, 9, 20) and chimpanzees (5, 7) .
Another point to consider is that we are only evaluating humoral responses in this comparison of IM (22) (23) (24) (25) . Thus, it is still possible that with IM injection of DNA vaccines there is direct transfection of nonmuscle cells such as professional antigen-presenting cells (APC) and that these cells are primarily responsible for the induction of immune responses. In fact, strong immune responses can be obtained by immunization solely with stably transfected dendritic cells (26) , and this is likely the effector cell-type involved after ID or gene-gun delivery of DNA vaccines (27) . Naked DNA transfects mature muscle fibers far more efficiently than mononuclear cells under in vivo conditions; however, the opposite is generally true of DNA formulated with cationic liposomes (28, 29 
